OP0223 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

TY - GEN

T1 - OP0223 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

AU - Genovese, MC

AU - Lertratanakul, A

AU - Anderson, J

AU - Papp, K

AU - Tillett, W

AU - Van den Bosch, F

AU - Tsuji, S

AU - Dokoupilova, E

AU - Keiserman, M

AU - Wang, X

PY - 2020/5/1

Y1 - 2020/5/1

UR - http://scientific.sparx-ip.net/archiveeular/?c=a&searchfor=tillett&view=1&item=2020OP0223

M3 - Other contribution

PB - BMJ Publishing Group Ltd

ER -